Equity
€75,614 ▼ 27.8%
DSMed paid out €90,394 in dividends. That is 147% of the 2025 profit.
DSMed
Lifetime
9 annual accounts with figures on one time axispeak €108,088 (2021)
€106,916▲ 10.4%
peak €61,319 (2025)
€61,319▲ 13.4%
peak €104,689 (2024)
€75,614▼ 27.8%
€383,730▲ 19.9%
Board2 names since 2017
2 directors and 1 other
Documentsfilings and deeds
31-07-2026on the last day
2025micro format
Dividend €90,394Equity from €104,689 to €75,614Debts from €320,026 to €383,730Cash from €46,753 to €93,093
Key points
from the 2025 annual accountsTurnover
≈ €190,000 estimated
The micro format states no turnover.
Debts
€383,730 84% of the balance sheet
Financial debts 62%Suppliers 0%Other 37%
Of this, €144,249 falls due within a year.
Filings
9 annual accounts 3 late
The 2020 accounts came latest: 32 days after the end of the period.
Starting capital
€18,600 100 shares
Position in the sector
16.5%
Lower solvency than 82% of companies in human health. Sector median 63.1% · 21,330 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 2,684 companies had the same profile as DSMed has now. Each dot stands for 7 companies, two years later.
97.2%
were still trading
1.3%
stopped another way
1.3%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 2,684 companies, not a prediction for DSMed. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Manager, since 12-01-2017
Director, since 12-01-2017
- 100 sharesdeed of 12-01-2017
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0668931695
Change of role: , from manager to director
Legal-form conversion: from private limited company (pre-2019) to private limited company · General meeting of 19-12-2022 · Gazette deed
New establishment in Wavre
Venelle du Tribut 11
Incorporation
Founding capital of €18,600, 100 shares, €12,400 paid up · Founder: · Appointment: (manager) · published on 12-01-2017 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| DSMed Walhain | €459,345 | €106,916 | 16.5% | - |
| STEPHANIE WILMS Balen | €482,812 | €107,238 | 77.8% | - |
| DOKTERSPRAKTIJK KOEN MEUS Pelt | €468,099 | €116,002 | 28.8% | - |
| Dokter Ana Malfait, huisarts Ternat | €490,510 | €115,902 | 62.0% | - |
| Dr. E. Kruitwagen Duffel | €479,770 | €114,655 | 78.4% | - |
| Dr. Mieke Delameilleure Houthulst | €410,957 | €114,216 | 72.4% | - |
| DR. REEKMANS ISABEL, HUISARTS Zulte | €393,823 | €103,092 | 76.5% | - |
These companies have the same main activity as DSMed: general medical practice (NACE 86210). They are comparable in size and age: total assets between €394,000 and €491,000, founded between 2015 and 2017.
Official details
Source: KBO- Status
- Active since 10-01-2017Normal situation
- Activity
- General medical practiceNACE 86210
- Establishment units
- 2.260.235.6021457 Walhain, since 10-01-2017
- 2.336.193.4311301 Wavre, since 12-05-2021
- Financial year end
- 31 December
- Peppol
- Reachable since 12-12-2025
Annual accounts 2025
- €459,345▲ 8.2%
- Filing
- Filed on 31-07-2026, on the last day of the filing period
Insights on DSMed
DSMed files the micro format. That format states no turnover. The gross margin rose from €35,698 in 2017 to €106,916 in 2025.
The balance sheet grew most from 2019 to 2021 through fixed assets.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about DSMed
- What is the company number of DSMed?
- The company number of DSMed is 0668.931.695. The VAT number is the same number with BE in front: BE 0668.931.695.
- Where is DSMed based?
- The registered office is at Rue des Trois Fontaines 26, 1457 Walhain.Company details
- What does DSMed do?
- According to the KBO register, the main activity is general medical practice (NACE 86210).
- What is the legal form of DSMed?
- DSMed is a private limited company (BV).
- When was DSMed founded?
- DSMed was founded on 10-01-2017.
- Is DSMed still active?
- Yes, DSMed is an active enterprise in the KBO register.
- What is the turnover of DSMed?
- The turnover in financial year 2025 is ≈ €190,000. This figure is estimated from the gross margin of €106,916 and 30 comparable companies (NACE 86210). It probably lies between €150,000 and €240,000.Financials
- Is DSMed profitable?
- In financial year 2025, DSMed made a profit of €61,319.
- Where can I find the annual accounts of DSMed?
- DSMed filed 9 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of DSMed due?
- DSMed must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.